Impact BioMedical (IBO) said Monday it agreed to merge with Hong Kong-based pharmaceutical group Dr. Ashleys that will result in a newly formed entity under "Dr Ashleys Limited."
Shares of Impact jumped 350%, with intraday trading volume of over 379 million against a daily average of about 6.81 million.
Cidara Therapeutics (CDTX) shares doubled after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults met its primary and all secondary efficacy endpoints for all dose groups.
RBC raised its price target on the stock to $75 from $35 while maintaining its outperform rating.
More than 5.25 million shares of Cidara traded intraday, compared with a daily average of about 171,000.
SpartanNash (SPTN) said it agreed to be acquired by C&S Wholesale Grocers for $26.90 per share for a total purchase price of $1.77 billion.
Shares of SpartanNash soared 50% as trading volume surged to over 7.1 million shares from a daily average of roughly 323,000.
Price: 1.70, Change: +1.34, Percent Change: +369.51
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.